Vaxcyte, Inc.
PCVXNASDAQHealthcareBiotechnology
Previous close
$62.62
+$1.28 · +2.09%
Pre-market
$62.62
$0.00 · 0.00%
Aug 24, 8:49 AM ET
PCVX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
34
Expensive
Momentum
53
Neutral
Sentiment
49
Mixed
Risk resilience
60
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteVaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Grant E. Pickering
- Listed since
- Jun 12, 2020
- Employees
- 507
Market position
Day range
Current $62.62
52-week range
Current $62.62
- Open
- $61.85
- Previous close
- $61.34
- Volume
- 1.14M
- 0.81× average
- Average volume
- 1.41M
- Average daily volume
- Market cap
- 9.04B USD
- Beta
- 1.21
- Market reference 1
- 50-day average
- $56.1242
- +11.57% above average
- 200-day average
- $53.2198
- +17.66% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 6.33B USD
- P/E (TTM)
- -8.2×
- P/B (TTM)
- 3.28×
- P/S (TTM)
- 0×
- EV / EBITDA
- -8.54×
- Earnings yield
- -12.21%
- Free cash flow yield
- -10.66%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -28.55%
- Return on assets
- -25.17%
- Return on invested capital
- -32.45%
Financial health
- Debt / equity
- 0.04×
- Current ratio
- 7.91×
- Altman Z-score
- 12.4
- Piotroski F-score
- 0 of 9
Earnings
- EPS beat rate
- 36%
- 4 beats, 7 misses, 0 met estimates
- Average EPS surprise
- -11.82%
- 11 comparable reports
- Latest EPS result
- -1.97
- Estimate -2.06 · Beat by 4.37%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$89.00
42.13% upsidePCVX news
PCVX peers
ETFs holding PCVX
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI249.06M0.01%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM206.93M0.26%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Small-Cap ETFVB179.55M0.10%183.4B USD0.03%$304.76+0.64%
State Street SPDR S&P Biotech ETFXBI140.9M1.24%11.39B USD0.35%$165.73+1.44%
Vanguard Morningstar Small-Cap Growth ETFVBK103.91M0.23%43.8B USD0.05%$358.65+0.70%
Vanguard Extended Market ETFVXF81.83M0.09%93.7B USD0.05%$245.53+0.82%
iShares Biotechnology ETFIBB64.73M0.61%10.75B USD0.44%$213.56+1.29%
T. Rowe Price Capital Appreciation Equity ETFTCAF59.56M0.72%8.27B USD0.31%$42.46+0.35%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 249.06M
- Weight
- 0.01%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 206.93M
- Weight
- 0.26%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 179.55M
- Weight
- 0.10%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
State Street SPDR S&P Biotech ETFXBI- Market value
- 140.9M
- Weight
- 1.24%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $165.73+1.44%
Vanguard Morningstar Small-Cap Growth ETFVBK- Market value
- 103.91M
- Weight
- 0.23%
- AUM
- 43.8B USD
- Expense ratio
- 0.05%
- Price / 1D
- $358.65+0.70%
Vanguard Extended Market ETFVXF- Market value
- 81.83M
- Weight
- 0.09%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Biotechnology ETFIBB- Market value
- 64.73M
- Weight
- 0.61%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
T. Rowe Price Capital Appreciation Equity ETFTCAF- Market value
- 59.56M
- Weight
- 0.72%
- AUM
- 8.27B USD
- Expense ratio
- 0.31%
- Price / 1D
- $42.46+0.35%
Continue in GoAI
Research PCVXresearch.disclaimer